Entera Bio Ltd.


ENTX

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001638097

D

fourth fifth of 369 graded peers in healthcare

rank 238 of 369; percentile 64.4; sampling error 2.5 points; lower is stronger




D, the sloth




Scoreboard	
Profitability	C percentile 54.4
Solvency	C percentile 50.1
Growth and financing	C percentile 54.9
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $16.0M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	degenerate inputs not computable: distress, fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 27, 2026 219 days before the rescan; latest periodic filing 10-Q received Aug 7, 2026
Last close	$3.19 2026-10-30; market equity $553.2M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

Entera is a clinical stage company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies. We concentrate on underserved, chronic medical conditions for which oral administration of a protein therapy has the potential to significantly shift a treatment paradigm. Our pipeline includes differentiated, first-in-class oral peptides targeting PTH(1-34), GLP-1/Glucagon and GLP-2: Currently, most protein therapies are administered via frequent intravenous, subcutaneous or intramuscular injections.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 54.4						
Gross profitability	0.0%	32.4%		95.8	366	2025-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(32.1%)	(6.6%)	13.1	803	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
annual revenue must exceed $100,000					
Solvency, sleeve percentile 50.1					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(20.27)	(0.35)	74.0	748	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	6.94x	2.92x	26.2	829	2025-12-31
Growth and financing, sleeve percentile 54.9					
Revenue growth, three-year compound	(32.1%)	10.1%	92.0	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
NOPAT must exceed $100,000					
Asset growth, three years	6.8%	2.2%	37.6	696	2025-12-31
Net share issuance, one year	2.6%	2.5%	35.2	631	2026-03-23


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
233	AbbVie Inc. (ABBV)	63.0	D	
234	Royalty Pharma plc (RPRX)	63.3	D	
235	Arvinas, Inc. (ARVN)	63.6	D	short runway, fortress balance sheet
236	Integra Lifesciences Holdings Corp. (IART)	63.9	D	
237	Organogenesis Holdings Inc. (ORGO)	64.1	D	fortress balance sheet
238	Entera Bio Ltd. (ENTX)	64.4	D	degenerate inputs
239	Caribou Biosciences, Inc. (CRBU)	64.7	D	short runway
240	Fulgent Genetics, Inc. (FLGT)	64.9	D	short runway
241	Dentsply Sirona Inc. (XRAY)	65.2	D	
242	AIM ImmunoTech Inc. (AIM)	65.5	D	late filer, degenerate inputs, distress
243	Angiodynamics Inc. (ANGO)	65.8	D	fortress balance sheet

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	0.0%	(2.2%)	51
Distance from 52-week high	(18.4%)	(28.7%)	64
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	(1.3%)	(1.0%)	48
Book value to price	0.01	0.28	14
Sales to price	0.00	0.30	1
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(0.17)	(0.19)	51

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$11.3M
Operating cash flow, four quarters	-$10.9M
Months of runway	12.5
Days since last periodic filing	86 (10-Q received Aug 7, 2026)
Median daily dollar volume, 63 sessions	$1.1M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$0	2025-12-31	2026-03-27	10-K	26-001797
2	assets	us-gaap:Assets	$16.0M	2025-12-31	2026-03-27	10-K	26-001797
3	net income	us-gaap:NetIncomeLoss	-$11.4M	2025-12-31	2026-03-27	10-K	26-001797
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$7.4M	2025-12-31	2026-03-27	10-K	26-001797
5	assets	us-gaap:Assets	$9.4M	2024-12-31	2026-03-27	10-K	26-001797
6	revenue	us-gaap:Revenues	$42,000	2025-12-31	2026-03-27	10-K	26-001797
7	current assets	us-gaap:AssetsCurrent	$15.3M	2025-12-31	2026-03-27	10-K	26-001797
8	current liabilities	us-gaap:LiabilitiesCurrent	$2.2M	2025-12-31	2026-03-27	10-K	26-001797
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$125.4M	2025-12-31	2026-03-27	10-K	26-001797
10	operating income	us-gaap:OperatingIncomeLoss	-$11.5M	2025-12-31	2026-03-27	10-K	26-001797
11	book equity	us-gaap:StockholdersEquity	$13.1M	2025-12-31	2026-03-27	10-K	26-001797
12	liabilities	us-gaap:Liabilities	$2.9M	2025-12-31	2026-03-27	10-K	26-001797
13	revenue	us-gaap:Revenues	$181,000	2024-12-31	2026-03-27	10-K	26-001797
14	revenue	us-gaap:Revenues	$0	2023-12-31	2025-03-28	10-K	25-001112
15	revenue	us-gaap:Revenues	$134,000	2022-12-31	2024-03-08	10-K	24-000881
16	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$107,000	2025-12-31	2026-03-27	10-K	26-001797
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$6.8M	2024-12-31	2026-03-27	10-K	26-001797
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3,000	2024-12-31	2026-03-27	10-K	26-001797

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$7.3M	2023-12-31	2025-03-28	10-K	25-001112
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$17,000	2023-12-31	2025-03-28	10-K	25-001112
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$12.5M	2022-12-31	2024-03-08	10-K	24-000881
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$47,000	2022-12-31	2024-03-08	10-K	24-000881
23	depreciation amortization	us-gaap:Depreciation	$30,000	2025-12-31	2026-03-27	10-K	26-001797
24	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$11.4M	2025-12-31	2026-03-27	10-K	26-001797
25	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2025-12-31	2026-03-27	10-K	26-001797
26	current assets	us-gaap:AssetsCurrent	$9.0M	2024-12-31	2026-03-27	10-K	26-001797
27	current liabilities	us-gaap:LiabilitiesCurrent	$1.2M	2024-12-31	2026-03-27	10-K	26-001797
28	assets	us-gaap:Assets	$11.8M	2023-12-31	2025-03-28	10-K	25-001112
29	assets	us-gaap:Assets	$13.1M	2022-12-31	2024-03-08	10-K	24-000881
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	46,622,239	2026-03-23	2026-03-27	10-K	26-001797
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	45,420,676	2025-03-20	2025-03-28	10-K	25-001112

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.